Get In Touch With Legato Biologics
Why Choose Legato Biologics?
Legato Biologics stands out as a premier CRDMO partner, offering uni-Qon™ technology, an industry-leading site-specific conjugation platform that enables the development of superior Antibody-Drug Conjugates (ADCs). Our proprietary approach ensures precise control over drug-to-antibody ratios, enhancing efficacy while minimizing off-target toxicity. Whether your project requires mono- or dual-payload ADCs, Legato Biologics provides an innovative and reliable solution to advance your therapeutic pipeline.
We provide comprehensive CMC services that cover the entire biologics development process under one roof, streamlining workflows and reducing complexity for our partners. From early discovery, through clinical trials, to commercial production, our integrated approach ensures a seamless journey, optimizing efficiency, timelines, and costs. Our expert team specializes in tackling challenging proteins that are difficult to express, leveraging cutting-edge technologies and a wealth of experience to solve even the most complex biologics development problems.
Legato Biologics’s proven track record of delivering high-quality results at low costs and with rapid turnaround times makes it a trusted partner for biotech and pharmaceutical companies worldwide. Our commitment to innovation is evident through our proprietary platforms, which drive next-generation therapeutic solutions, offering unique capabilities that set us apart in the industry.
With a strong global presence and strategic partnerships with leading pharmaceutical companies, Legato Biologics has established itself as a reliable and forward-thinking collaborator in the biopharmaceutical space. Our unwavering commitment to quality ensures strict adherence to GMP, GLP, and other regulatory requirements at every stage of development. By choosing Legato Biologics, you gain a dedicated partner focused on delivering excellence, reducing risks, and accelerating your product’s journey to market success.
